Shots:

• Seattle to receive upfront plus progress-dependent milestones of up to $160M and royalties on any product sales- retaining rights for candidates in Americas (the US- Canada- and Latin American countries)- EU and Japan. BeiGene to get exclusive rights to develop and commercialize the candidates in Asia (Ex- Japan) and ROW and will also be responsible for all clinical development and regulatory submissions
•  The focus of the agreement is to advance preclinical candidates utilizing Seattle Genetics’ antibody-based technology with expected advancement to clinical trials in H1’20
• Seattle’s ADC Technology harness the ability of antibodies to deliver cell-killing agents and combines the specificity of mAbs- innovative linker systems- and the power of potent cell-killing agents for the treatment of cancer

Click here to­ read full press release/ article | Ref: Seattle Genetics | Image: Twitter